Abstract: An agent for elevating nitric oxide (NO) concentration comprising glutathione or a salt thereof as an active ingredient; an agent for elevating NO concentration comprising glutathione or a salt thereof as an active ingredient for preventing or ameliorating a vascular endothelial malfunction-related symptom, or dilating blood vessels or promoting blood flow by elevating NO concentration; and a method for elevating NO concentration by ingesting glutathione or a salt thereof.

Abstract: An object of the present invention is to provide a microorganism that efficiently produces EPA and a method for producing EPA using the microorganism. The present invention relates to a microorganism having an ability to produce docosahexaenoic acid (DHA), wherein the microorganism contains a protein composed of an amino acid sequence in which at least one of the amino acid residues at positions 6, 65, 230, 231, and 275 in the amino acid sequence represented by SEQ ID NO: 2 has been substituted with another amino acid residue (mutated OrfB), and is capable of producing eicosapentaenoic acid (EPA), and the like.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Parkinson's disease, comprising a 2-(4-(1-hydroxypropane-2-yl)phenyl)isoindoline-1-one compound or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition for preventing or treating Parkinson's disease can increase the protein level of PGC-1? in the brain of an individual by successfully passing through the blood-brain barrier (BBB).

Abstract: The present invention relates to a novel chimeric antigen receptor and to a pharmaceutical composition for preventing or treating containing the same.

Abstract: The present invention relates to an antibody specific for CD22 and uses thereof, and more particularly to an antibody that specifically binds to CD22, a chimeric antigen receptor comprising the antibody, a CAR-T cell expressing the chimeric antigen receptor, and a pharmaceutical composition for preventing or treating diseases mediated by cells expressing CD22 including the same. It was confirmed that the antibody selected in the present invention specifically recognized CD22-expressing cells, and the chimeric antigen receptor (CAR) and CAR-T cells targeting CD22 using the CD22-specific antibody not only effectively bound to CD22, but also activated CAR-T cells bound to CD22. In addition, since it was confirmed that the CAR-T cells of the present invention effectively kill CD22-expressing cells, the CD22-specific antibody, the chimeric antigen receptor targeting CD22, and CAR-T cells of the present invention can be usefully used as a composition for preventing or treating diseases relating to CD22 expression.

Abstract: The invention provides a method for improving attention of a healthy human subject by administering an effective amount of citidine-5?-diphosphocholine or a salt thereof to a healthy human subject.

Abstract: The present invention relates to a lipolysis composition comprising a biocompatible polymer that is surface-modified by an adipocyte-targeting or cell-penetrating peptide; and surface-modified gas-generating nanoparticles that contain fine-grained calcium carbonate crystals enclosed in the biocompatible polymer.

Abstract: A method for treating cancer in a patient who is resistant to a protein kinase inhibitor, administering an anticancer agent containing, as an active ingredient, a thienopyridine derivative compound or a pharmaceutically acceptable salt thereof is disclosed. Here, the patient may carry active RON. In addition, the patient may carry normal KRAS gene. In addition, the anticancer agent may be applied to a patient who is resistant to an EGFR inhibitor. In particular, the anticancer agent may be usefully used to treat a patient who is resistant to the therapeutic agent cetuximab.

Abstract: An agent for elevating nitric oxide (NO) concentration comprising glutathione or a salt thereof as an active ingredient; an agent for elevating NO concentration comprising glutathione or a salt thereof as an active ingredient for preventing or ameliorating a vascular endothelial malfunction-related symptom, or dilating blood vessels or promoting blood flow by elevating NO concentration; and a method for elevating NO concentration by ingesting glutathione or a salt thereof.

Abstract: The present invention relates to a method for extracting nucleic acids from a biological sample, and the extraction method presents a novel method for effectively extracting nucleic acids. When nucleic acids are extracted from biological samples in the related art, various impurities present in the biological samples are not properly removed, such that the purification rate is low, but the present invention provides a method for extracting nucleic acids from a biological sample of which the bacteria, virus and nucleic acid recovery rates are enhanced, by adding a surfactant and a sodium sulfate (Na2SO4) solution in a biological sample disruption step and a purification step, thereby enabling pathogens to be detected more sensitively and accurately.

Abstract: A pharmaceutical composition that is useful preventing or treating cancer with a KRAS mutation and activated RON is disclosed. The pharmaceutical composition may be utilized as an anticancer drug that exhibits an excellent cell death-inducing ability on cancer cells with KRAS G13 mutation or KRAS G12 mutation and a RON mutation or tyrosine-phosphorylated RON (pTyr-RON).

Abstract: The present invention relates to a gas-generating micelle for reducing localized fat. In the present invention, by forming a micelle using a material having high biocompatibility and also introducing a cell-targeting ligand (peptide) onto the surface of the micelle, delivery to surrounding cells and tissues other than adipocytes can be minimized, and delivery into adipocytes can be maximized. The gas-generating micelle for reducing localized fat according to the present invention can be produced as an injectable preparation, and can be applied to local lipolysis supplements or diet beauty products that break down localized fat.

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of muscle disease comprising a Panax ginseng berry extract as an active ingredient. The composition of the present invention alleviates the decrease in muscle weight and muscle fiber cross-sectional area caused by muscle atrophy, and reduces the increase in expression of MuRF-1 (Muscle RING-finger protein-1) and atrogin-1, which are involved in proteolysis of muscle proteins, so that it can be effectively used to prevent, ameliorate or treat muscle disease.

Abstract: An object of the present invention is to provide a microorganism that efficiently produces EPA and a method for producing EPA using the microorganism. The present invention relates to a microorganism having an ability to produce docosahexaenoic acid (DHA), wherein the microorganism contains a protein composed of an amino acid sequence in which at least one of the amino acid residues at positions 6, 65, 230, 231, and 275 in the amino acid sequence represented by SEQ ID NO: 2 has been substituted with another amino acid residue (mutated OrfB), and is capable of producing eicosapentaenoic acid (EPA), and the like.

Abstract: An agent which can play a comparable or superior role to LS in improvement of intestinal tract function, enhancement of immune function, suppression of production of a putrefactive product, improvement of bowel movement or the like and an agent which can play a role in protection of the intestinal tract from a food emulsifier, a lipid peroxide or the like are provided. An intestinal tract function-improving agent, an immunoenhancing agent, a putrefactive product production-suppressing agent, a bowel movement-improving agent and an intestinal tract protection agent each containing a cyclodextrin as an active ingredient are provided. they can play a comparable or superior role to LS in improvement of intestinal tract function, enhancement of immune function, suppression of production of a putrefactive products, improvement of bowel movement or the like and the agent which can play a role in protection of the intestinal tract from a food emulsifier, a lipid peroxide or the like.

Abstract: The present invention provides a kidney production method including a step of tissue-specifically removing a metanephric mesenchyme of a metanephros of a non-human animal; a step of transplanting a human kidney precursor cell into the metanephros; and a step of advancing development of the metanephros, which is a step in which the transplanted human kidney precursor cell is differentiated and matured to form a part of the kidney.

Abstract: A method for manufacturing a fucoidan cosmetic composition includes: washing mozuku to eliminate residual salt and impurities; adding citric acid to the washed mozuku and pulverizing the mozuku; adding water to the pulverized mozuku and performing reflux extraction to obtain a high molecular weight fucoidan; adding a neutralizing agent to the high molecular weight fucoidan for neutralization; adding diatomite to the neutralized high molecular weight fucoidan and causing a reaction for 30 minutes for deodorization; filtering the deodorized high molecular weight fucoidan to eliminate insoluble substances; adding a lactic acid bacterium to the high molecular weight fucoidan removed of the insoluble substances and causing fermentation to obtain a low molecular weight fucoidan; concentrating the purified low molecular weight fucoidan with a reduced pressure evaporator; and powdering the concentrated low molecular weight fucoidan through freeze drying.

Abstract: The present invention relates to a method of quickly preparing a large amount of octacalcium phosphate and octacalcium phosphate prepared thereby. A method of preparing octacalcium phosphate according to an embodiment of the present invention includes preparing a calcium phosphate solution, controlling an initial pH by controlling a pH of the calcium phosphate solution to a range from 5 to 6 using an acidic solution at a time point at which the pH of the calcium phosphate solution increases, heating the calcium phosphate solution to a temperature ranging from 60° C. to 90° C., and controlling a terminal pH by controlling the pH of the calcium phosphate solution to a range from 5 to 6 using a basic solution at a time point at which the pH of the heated calcium phosphate solution decreases.

Abstract: A method of improving both motor function and cognitive function of healthy human subjects through administration of citicoline or its salt in high dosage or low dosage for a period of time, resulting in improved motor function and cognitive function.

Abstract: The present invention relates to a medical composition and a method for preparing the same, the medical composition comprising: an adipose tissue-derived extracellular matrix powder; and a biocompatible polymer or a crosslinked product of the biocompatible polymer. The medical composition according to the present invention exists in a well-aggregated state even after implantation in the body and can maintain the volume thereof for a certain time.